Sickle Cell Disease: Local or Global Solutions for the Global Reduction of Disease Burden
11 January 2017 12:00 to 13:00 EST
220 Mass. Avenue, Cambridge MA - USA
Speaker: Stephen K. Obaro, M.D., FWACP, MRCP(UK), FRCPCH, Ph.D. Professor, Pediatric Infectious Diseases Director, Pediatric International Research University of Nebraska Medical Center, Omaha, NE
Trustee, International Foundation Against Infectious Disease in Nigeria
Seminar Abstract: This presentation will review the pathology of sickle cell disease, current management strategies and discuss a model for generating and adopting local approaches for the reduction of the global disease burden.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Spencer. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Speaker | Dr. Stephen Obaro
Dr. Stephen Obaro is a Professor of Pediatric Infectious Diseases and the Director of Pediatric International Research at the University of Nebraska Medical Center in Omaha, Nebraska. Over the past eight years Dr. Obaro has been working in Nigeria conducting research to improve the health of children by development of an infectious disease surveillance platform. Information gathered from this platform is used to develop new tests and vaccines as well as inform medical interventions. His research is novel in that it is the first of its scale in Nigeria.
Dr. Obaro’s training is in general pediatrics, immunology and infectious disease. He has over 20 years of research and clinical practice experience in West Africa, with particular focus on detection and management of invasive bacterial infections, as well as immunization strategies. He completed his medical training in Nigeria followed by clinical research experience at the UK Medical Research Council Laboratories in The Gambia and postdoctoral training at the University of Massachusetts, where he worked on immune responses to vaccine antigens in HIV- infected children. As project leader, he established the groundwork for the pneumococcal conjugate vaccine studies in The Gambia; the only study which has till date, demonstrated efficacy of the vaccine against all-cause mortality. He currently leads a research team in Nigeria, which recently established surveillance for community acquired bacteremic syndromes, utilizing state-of-the-art diagnostic culture based methods in children.